

4Kscore®

A DIAGNOSTIC BLOOD TEST FOR DETECTING THE RISK OF AGGRESSIVE PROSTATE CANCER

ACCURACY DEMONSTRATED BY ONGOING CLINICAL RESEARCH CONDUCTED BY LEADING INTERNATIONAL CANCER CENTERS

| REFERENCE | COHORT | # OF SUBJECTS | AUC AGGRESSIVE PROSTATE CANCER |
|--|---------------------------------|---------------|--------------------------------------|
| A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. Br J Cancer 2010; 103(5): 708–714 | Prior biopsy | 925 | 0.87 |
| A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Urol 2014; 68(3):464-470 | Prior biopsy No prior biopsy | 1,012 | 0.82 |
| A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med. 2008; 6(1): 19 | No prior biopsy | 740 | 0.90 |
| A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010; 10(1): 635 | No prior biopsy | 262 | 0.87 |
| Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. J Clin Oncol. 2010; 28(15): 2493–2498 | No prior biopsy | 2,914 | 0.84 |
| A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010; 16(12): 3232–3239 | No prior biopsy | 1,501 | 0.80 |
| Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated PSA: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010; 116(11): 2612-2620 | No prior biopsy | 1,241 | 0.83 |
| Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. J Natl Cancer Inst 2015; 107(7): djv095 | No prior biopsy | 6,129 | 0.82 |
| A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol. 2016 Mar;69(3):505-11. | No prior biopsy | 749 | 0.78 |
| Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. Eur Urol 2013; 64(5): 693-699 | Radical Prostatectomy | 392 | 0.84 |
| A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population- Based Cohort Followed for 15 Years without Screening. Cancer Epidemiol Biomarkers Prev. 2011; 20(2): 255-61 | Metastasis | 792 | 0.82 |
| Comparison between the four-kallikrein panel and Prostate Health Index (PHI) for predicting prostate cancer. Eur Urol 2015; 68(1): 139–146 | No prior biopsy | 531 | 0.72 |
| Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. J Urol. 2017;197(4):1041-1047 | No prior biopsy | 946 | 0.79 |
| Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostatespecific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study. Eur Urol 2015; 68 (2): 207-213 | Metastasis | 5360 | -- |

14 Peer-Reviewed Publications

Total Men Studied

23,494